Kiora Pharmaceuticals Inc(KPRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.64 | Insider Own | 11.64% | Shs Outstand | 4.4M | Perf Week | -2.66% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 49.1% | Insider Trans | - | Shs Float | 3.9M | Perf Month | -1.16% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.38 | Inst Own | 35.49% | Short Float | 0.1% | Perf Quarter | 0.39% |
| Income | -0.01B | P/S | - | EPS this Y | 36.74% | Inst Trans | 17.51% | Short Ratio | 0.23 | Perf Half Y | 31.96% |
| Sales | 0.00B | P/B | 0.67 | EPS next 5Y | 28.62% | ROA | -39.43% | Short Interest | 0.00M | Perf YTD | 29.95% |
| Book/sh | 3.81 | P/C | 0.67 | EPS past 3/5Y | 75.03% 65.58% | ROE | -56.36% | 52W High | -13.22% ($2.95) | Perf Year | -8.9% |
| Cash/sh | 3.81 | P/FCF | - | Sales past 3/5Y | - | ROIC | -64.56% | 52W Low | 45.08% ($1.76) | Perf 3Y | -51.79% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 19.38% | Gross Margin | - | Volatility(W/M) | 1.17% 3.41% | Perf 5Y | -99.65% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | -99.97% |
| Dividend Ex-Date | - | Quick Ratio | 8.97 | EPS Q/Q | 37.64% | Profit Margin | - | RSI (14) | 45.71 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.97 | Sales Q/Q | - | SMA20 | -2.18% ($2.62) | Beta | -0.18 | Target Price | $12 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/7 | SMA50 | -1.46% ($2.6) | Rel Volume | 0.2 | Prev Close | $2.58 |
| Employees | 13 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 27.66% - | SMA200 | 7.22% ($2.39) | Avg Volume(3M) | 0.02M | Price | $2.56 |
| IPO | 2015/2/13 | Option/Short | No/Yes | Trades | 52 | Volume | 3,436 | Change | -0.78% |
👁️ Kiora Pharmaceuticals (KPRX) is a clinical-stage biotech focused on retinal diseases. Its lead asset, KIO-301, is a "molecular photoswitch" being developed to restore retinal signal transmission in patients who have lost vision due to inherited and age-related retinal degeneration. The pipeline begins with retinitis pigmentosa (RP) and is planned to expand into indications such as choroideremia and Stargardt disease. A distinguishing feature of the company is its collaboration agreements with global ophthalmology partners, including Théa and Senju.
Over the past 1 year, roughly in the middle
13% below its 1-year high.
Traded less than usual That is 20% of its average volume.
KPRX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +36.7% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.7%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 35.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #501 of 592 in the industry
Based on market cap of $11M.
PHIO#500 Phio Pharmaceuticals Corp $11M PER - KPRX#501 Kiora Pharmaceuticals Inc $11M PER - 
INTS#502 Intensity Therapeutics Inc $11M PER - 
GTBP#503 GT Biopharma Inc $11M PER - 
LTRN#504 Lantern Pharma Inc $11M PER - 
FAQ
What kind of company is KPRX?
KPRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KPRX?
The market cap of KPRX is approximately $11M, ranking 5,448 within its sector.
What is the 52-week high and low for KPRX?
KPRX has recorded a 52-week high of $2.95 and a low of $1.76.
